Pacific Biosciences Of California (PACB) Common Equity (2010 - 2026)

Pacific Biosciences Of California has reported Common Equity for 17 years, with the latest figure at $2.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 97.42% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.4 million (down 97.42% YoY), and the FY2025 full-year result was $5.3 million, down 98.94% from the prior year.
• Common Equity for Q1 2026 stood at $2.4 million, down from $5.3 million in the prior quarter.
• The five-year high for Common Equity was $763.7 million in Q3 2023, with the low at $2.4 million in Q1 2026.
• Average Common Equity over 5 years is $453.1 million, with a median of $562.9 million recorded in 2022.
• Year-over-year, Common Equity soared 164.05% in 2022 and slumped 98.94% in 2025.
• Tracing PACB's Common Equity over 5 years: stood at $562.9 million in 2022, then increased by 24.59% to $701.3 million in 2023, then dropped by 27.76% to $506.6 million in 2024, then tumbled by 98.94% to $5.3 million in 2025, then sank by 55.77% to $2.4 million in 2026.
• The last three Common Equity figures came in at $2.4 million (Q1 2026), $5.3 million (Q4 2025), and $36.1 million (Q3 2025), per Business Quant data.

Peer Comparison